Topic Listing for DGI RESOLUTION INC

Able Continue Operations Near Term Incur Operating Losses Accidents Illness
Accounting Certain Transactions Involving Stock Compensation-an Interpretation Apb Accounting Conditional Asset Retirement Obligations-an Interpretation Fasb Statement
Accounting Impairment Disposal Long-lived Assets Accounting Matters
Accounting Stock Issued Employees Accounting Stock-based Compensation
Accrued Expenses Other Current Liabilities Acknowledge Signing Agreement Waiving Right Jury Trial Before
Acknowledged Agreed Acquisition Uvs
Acquisitions In-licensing Acquisitions Joint Development Programs In-licensing
Additional Information Regarding Chapter Case Additional Service Offerings
Adjustment Provisions Adjustments Changes Stock
Administration Administrator
Adoption Change Control Benefits Plan Adoption Date
Adoption Fasb Interpretation Advancing Clinical Pipeline Major Indications Unique Capabilities Human
Advancing Development New Drugs Heart Attack Peripheral Artery Adverse Change
Adversely Impacted Economic Factors Beyond Control Incur Additional Affect Future Results
Agreement Agreements
Amendment Amendment Termination Plan
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Conflicts Annual Base Salary
Annual Bonus Annual Meeting Stockholders 2008
Appendix Apply Net Proceeds Sale Shares Being Sold Set
Appraisal Rights Approval Amendment Amended Restated Certificate Incorporation Increase Authorized
Approval Decode Genetics Inc 2006 Equity Incentive Plan Arterial Thrombosis Dg041
Assignment Assumption Role Genes Disease Wrong Not Able Develop
Assumption Role Genes Diseases Wrong Not Able Develop Asthma
Asthma Cep-1347 Atherosclerosis Dg041
Attachment Attachments
Auction Rate Securities Audit Committee
Audit Committee Pre-approval Permissible Non-audit Services Audit Committee Pre-approval Permissible Non-audit Services Independent Accountants
Audit Committee Pre-approval Permissible Non-audit Services Independent Registered Audit Committee Report
Authorized Shares Autism
Awards Equity Incentive Plans Axel Nielsen
Banks Rights Remedies Base Salaries
Base Salary Basis Presentation
Bayer Healthcare Because Revenues Concentrated Loss Significant Customer Harm Business
Beneficial Ownership Reporting Compliance Benefits Employment Agreements
Birgit Stattin Norinder Bladder Cancer
Board Board Committees
Board Directors Corporation Board Time Terminate Amend Modify Suspend Plan Provided
Bone Mineral Density Breach Employees Contractual Obligations
Breast Cancer Business
Cannot Successfully Develop Marketing Sales Force Maintain Suitable Cannot Successfully Form Maintain Suitable Arrangements Parties Manufacturing
Capital Business Structure Merge Consolidate Dissolve Liquidate Sell Capital Leases
Case Nonqualified Stock Option Date Such Termination Employment Cash Equivalents
Cash Investments Cash Position
Cash Position Ars Cash Stock Bonuses
Cause Cautionary Statement Regarding Financial Operating Data
Celera Celera License
Certain Relationships Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Risks Associated Reverse Stock Split
Certification Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Change Accountants Change Control
Change Control Benefits Plan Change Control Means Occur Following
Changes Internal Controls Changes Outsourcing Trends Economic Conditions Pharmaceutical Biotechnology Industries
Changing Vote Check Appropriate Box Below Form 8-k Filing Intended
Chief Executive Officer Compensation Claim
Class Clinical Programs
Clinical Programs Dg031 Prevention Heart Attack Clinical Programs Dg041 Treatment Pad
Clinical Programs Party Compound Asthma Clinical Progress Asthma Pad Heart Attack Advances Preclinical
Clinical Trials Required Product Candidates Partners Expensive Time-consuming Clinical Trials Required Product Candidates Products Customers Partners
Closing Closing Date
Clyde Shores Co-development Therapeutic Diagnostic Products Required Delays Development Approval
Code Ethics Code Internal Revenue 1986 Amended
Collaborations Collaborations Revenue
Collateral Value Commence Chapter Bankruptcy Proceeding Operating Code Restrict Ability
Commercial Success Products Develop Depend Degree Market Acceptance Committees Meetings Board Directors
Common Stock Common Stock 001 Par Value
Common Stock De-listed Nasdaq Seriously Limit Liquidity Common Stock Subject Plan
Compensation Arrangements Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Philosophies Compensation Philosophy
Compensatory Arrangements Chief Operating Officer Competition
Completes Latest Clinical Trials Heart Attack Anti-platelet Compounds Completion Acquisition Disposition Assets
Components Compensation Comprehensive Income
Computation Net Loss Per Common Share Computation Net Loss Per Share
Con Concentration Risk
Concerns Regarding Genetic Testing Results Limit Commercial Viability Condensed Consolidated Balance Sheet Data
Condition Delivery Alteration Maintenance Leased Property Conditions Placement Agents Obligations
Conference Call Discuss Results Recent Operating Highlights Webcast Conference Call Discuss Results Recent Progress Drug Development
Conference Call Information Confidential
Confidential Treatment Requested Confidentiality Invention Assignment Non-compete Agreement
Confronted Serious Liquidity Concerns Threaten Operations Consent Independent Registered Public Accounting Firm
Consideration Consultant
Continue Incur Operating Losses Longer Anticipated Amounts Greater Contract Genotyping Services
Contracts Terminate Short Notice Contribution
Controls Procedures Conveyance Title
Corporate Alliances Corporate Compliance Program Cannot Guarantee Applicable Federal State
Corporation Decode Genetics Inc Delaware Corporation Liquidated Sells Otherwise Disposes Substantially Assets Single
Cost Revenue Cost Revenue Including Collaborative Programs
Costs Associated Exit Disposal Activities Course Trials Activities
Creation Direct Financial Obligation Off-balance Sheet Arrangement Creation Direct Financial Obligation Off-balance Sheet Arrangement Registrant
Critical Accounting Policies Currency Fluctuations Negatively Affect Financial Condition
Current Report Currently Not Intend Pay Dividends Common Stock Consequently
Custodial Trust Dan Hartman
Daniel Hartman Date Termination
Dated 2006 David Hermann Peter Van Ess
Debt Debtor Questionnaire
Decode Decode Advancing Lead Product Development Programs
Decode Announces Appointment Linda Buck Board Directors Decode Announces Changes Leadership Business Development
Decode Announces Dismissal Class-action Lawsuits Decode Announces Placement Convertible Notes
Decode Announces Positive Results Preliminary Phase Clinical Trial Decode Announces Positive Topline Results Phase Study Dg051
Decode Announces Proposed Convertible Notes Offering Decode Announces Special Protocol Assessment Agreement Fda Phase
Decode Appoints Senior Vice President Corporate Developmen Decode Breast Cancer
Decode Breastcancer Decode Celera Partner Expand Risk Markers Heart Attack
Decode Chemistry Inc Decode Completes Senior Convertible Notes Offering
Decode Describes Genetic Risk Factor Heart Attack Conferring Decode Discovers Major Genetic Risk Factor Prostate Cancer
Decode Discovers Major Genetic Risk Factor Type Diabetes Decode Discovers Variation Sequence Genome Conferring Risk Atrial
Decode Expands Cancer Program Through Acquisition Icelandic Research Decode Expands Drug Development Team
Decode Files Suit Defend Intellectual Property Decode Files Universal Shelf Registration Statement
Decode Gene Discovery Points New Approach Treating Major Decode Genetics
Decode Genetics Announces 2005 Financial Results Decode Genetics Announces 2006 Financial Results
Decode Genetics Announces 2007 Financial Results Decode Genetics Announces 2008 Financial Results
Decode Genetics Announces Full-year 2004 Financial Results Decode Genetics Announces Full-year 2005 Financial Results
Decode Genetics Announces Full-year 2006 Financial Results Decode Genetics Announces Full-year 2007 Financial Results
Decode Genetics Announces Full-year 2008 Financial Results Decode Genetics Inc
Decode Genetics Inc Index Decode Genetics Inc Initial Public Offering Securities Litigation
Decode Genetics Inc Proxy Solicited Behalf Board Directors Decode Genetics Inc Sturlugata Is-101 Reykjavik Iceland
Decode Illumina Form Alliance Develop Commercialize Dna-based Diagnostics Decode Initiates Phase Clinical Program Dg041 Peripheral Artery
Decode Initiates Phase Clinical Program Dg051 Prevention Heart Decode Initiates Phase Trial Dg031 Prevention Heart Attack
Decode Launches Novel Dna-based Test Assessing Inherited Risk Decode Launches Phase Clinical Testing Dg051 Prevention Heart
Decode Launches Phase Clinical Trial Asthma Decode Launches Test Major Genetic Risk Factor Early-onset
Decode Provides Drug Development Update Decode Provides Product Development Update
Decode Receives Nasdaq Bid Price Deficiency Notice Decode Receives Nasdaq Deficiency Notice Relating Market Value
Decode Requests Hearing Nasdaq Following Receipt Staff Determination Decode Shares Continue Trade Usual Pending Nasdaq Listing
Decode Submits Ind Dg051 Prevention Heart Attack Decode Successfully Completes Phase Clinical Program Dg041 Treatment
Decode Suspends Phase Trial Dg031 Improve Tablet Manufacturing Decodeme
Decodeme Not Profitable Decodes Programs Heart Attack
Deductibility Compensation Deferred Revenue
Defined Contribution Benefits Defined Contribution Plans
Definitions Delivery Payment Shares
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Dependence Collaborative Relationships Lead Delays Product Development Defects Derivative Financial Instruments
Description Property Designated Employee
Dg031 Dg031 Approved Fda Marketing Exclusivity Only Limited Term
Dg031 Dg051 Heart Attack Dg031 Dg051 Prevention Heart Attack
Dg041 Dg041 Arterial Thrombosis
Dg041 Prevention Arterial Thrombosis Dg041 Treatment Arterial Thrombosis
Dg051 Dg051 Dg031
Dg051 Dg031 Prevention Heart Attack Dg071
Dg071 Alzheimers Cognition Deficits Dg071 Alzheimers Other Cognitive Disorders
Dgi Resolution Inc Diabetes Breast Cancer Prostate
Diabetes Major Public Health Problem Diagnostic Tests Not Profitable
Diagnostics Diagnostics Breast Cancer
Diagnostics Decode Proca Diagnostics Gene Discovery
Diagnostics Glaucoma Director Attendance
Director Attendance Annual Meeting Director Compensation
Director Independence Director Nomination Process
Director Nominee Director Nominees
Directors Directors Executive Officers Registrant
Disability Disbursements Calculating Trustee Quarterly Fees Cur Rent Actual
Disbursements Calculating Trustee Quarterly Fees Current Actual Column Discretionary Authority
Dna Direct Dna-based Diagnostic Tests Consumer Genetic Analysis
Dna-based Diagnostics Dna-based Diagnostics Consumer Genetic Analysis
Documents Incorporated Reference Dose-dependent Reduction Leukotriene Ltb4
Drug Development Drug Development Programs
Drug Diagnostic Development Drug Discovery Development
Drug Discovery Development Services Duties
Duties Administrator Each Document Filed Pursuant Exchange Act Incorporated Reference
Earl Collier Earl Duke Collier
Effect Potential Delisting Common Stock Nasdaq Global Market Effective Date
Egal Proceedings Election Code
Election Directors Eligibility
Employee Employee Common Law Corporation Subsidiary Including Individual Employed
Employees Employment Agreements
Employment Contract Entry Material Definitive Agreement
Environmental Environmental Laws
Equipment Equipment Notes
Equity Awards Equity Bonus
Equity Compensation Plan Information Equity Incentive Plans
Escrow Account Escrow Agent
Escrow Agreement Escrow Funds
Establishment Plan Establishment Purpose Plan
Estimates Estimates Assumptions
Evaluation Disclosure Controls Procedures Evaluation Named Executive Officer Performance 2006
Evaluation Named Executive Officer Performance 2007 Evaluation Named Executive Officer Performance 2008
Ex-vivo Exchange Act
Executive Compensation Executive Officers
Executive Officers Not Directors Exercise
Exercise Options Following Termination Employment Service Exhibits Financial Statement Schedules
Exhibits Financial Statement Schedules Reports Form 8-k Exhibits Reports Form 8-k
Explanatory Fail Protect Confidential Data Adequately Incur Liability
Fair Market Value Fair Market Value Date
Fair Value Financial Instruments Fair Value Measurement
Fair Value Short-term Financial Instruments Fcpa
Federal Income Tax Consequences Federal Income Tax Consequences Reverse Stock Split
Fee-for-service Work Bears Certain Risks Liability Customers Fiduciary Duty
Field Work Finance
Finance Costs Related Long-term Debt Financial Condition
Financial Statements Exhibits Financial Statements Supplementary Data
Financing Activities Fold Detach Here
Following Financial Statements Included Part Annual Report Form Foreign Currency Translation
Foreign Exchange Transactions Form 10-k
Form 10-q Form Director Officer Lock-up Letter
Forward-looking Statements Forward-looking Statements Cautionary Factors Affect Future Results
Fractional Shares Fractional Shares Resulting Adjustment Awards Pursuant Settled Administrator
Further Agreements Placement Agents Agrees Future Sales Common Stock Dilute Stockholders
Gender General Information
General Provisions Geographic Information
Going Concern Good Reason
Goodwill Goodwill Other Intangibles
Governing Law Government Regulation
Government Research Contracts Grant Funding Grant Funding
Grant Revenue Gross Habitual Failure Perform Persons Assigned Duties Not
Guarantees Guaranty
Gurney Phd Göran Ando
Hakon Hakonarson Phd Health Welfare Employee Benefits Plans
Heart Attack Heart Attack Dg03
Heart Attack Dg031 Heart Attack Dg031 Dg051
Heart Attack Dg051 Heart Attack Dg051 Dg041
Heart Attack Lta4h Heart Attack Lta4h Inhibitor
Hibits Reports Form 8-k Hoffmann-la Roche
Hundred Icelandic Krónur Icelandic Economic Situation
Icelandic Subsidiary Decode Genetics Ehf Illumina
Illumina Install Large-scale Genotyping System Supply Humanhap300 Beadchips Impairment Employee Termination Benefits Other Charges
Impairment Long-lived Assets Impairment Long-lived Assets Goodwill
Incentive Stock Option Income Taxes
Increase Maximum Number Shares Common Stock Issued Plan Increased Leverage Result Convertible Debt Harm Financial Condition
Indemnification Indemnified Party
Indemnifying Party Indenture
Independence Index
Information Rich Clinical Trials Information-rich Clinical Trials
Insurance Insurance Guarantees Special Termination Provisions
Insurance Standards Intangible Assets
Intentional Material Violation Designated Employee Contract Between Corporation Intentionally Omitted
Interest Expense Interest Income
Interests Directors Executive Officers Internal Control-integrated Framework
Introduction Investing Activities
Investment Purpose Investments
Investor Investor Schedule
Investors Irrevocable Power Attorney
Issue Preferred Stock Rights Affect Prevent Takeover Business Issuer Free Writing Prospectus
Jakob Sigurdsson Jama
James Beery Joint Development Programs In-licensing
Kari Stefansson Med Krokhals
Lance Thibault Launch Decode
Launches Decode Test Risk Variant Aimed Prevention Stroke Lease
Lease Agreement Lease Amount Payment Rent Together Operating Cost
Lease Other Commitments Leases Finance Obligation
Led Discovery Genes Confer Risk Common Diseases Empowering Legal Description
Legal Proceedings Letter Credit Reimbursement Guarantee Security Pledge Agreement
License Agreement Limitation Incorporation Reference
Limitation Liability Linda Buck
Linda Buck Phd Listing Registration Shares
Litigation Litigation Other Contingencies
Location New Space Long-lived Assets Goodwill Intangibles
Long-term Debt Major Discovery Rapid Applicability Development New Medicine
Majority Holders Managements Discussion Analysis Financial Condition Results Operations
Managements Plans Managements Report Internal Control Over Financial Reporting
Market Common Equity Related Stockholder Matters Materials Supplies
Medichem Life Sciences Inc Meetings Board Directors Committees
Merck Inc Milestone Cancer Genetics Common Genetic Variant Conferring Significant
Milestone Payments Miscellaneous
Mitigation Exclusivity Benefits Certain Reduction Monday-friday Eastern Time
Money Laundering Laws Mortgage Bonds
Mortgage Loan Mortgage Loans
Mortgage Refinancing Most Recent Preliminary Prospectus
Most Significant Inherited Component T2d Yet Found Discovery Multiple Proxy Cards
Nasdaq Notification Nasdaq Stays Suspension Trading Decode Stock
National Institute Allergy Infectious Diseases Niaid National Institutes Allergy Infectious Diseases Niaid
Nature Nature Employment Obligations
Nature Genetics Neal Armstrong
Neither Notes Nor Shares Common Stock Issuable Conversion Net Loss Basic Diluted Per Share
Net Loss Per Common Share Net Loss Per Share
New Plan Benefits Table New Tool Better Understanding Risk Empowering Effective Prevention
Niaid Infectious Disease Nicotine Addiction Lung Cancer
Nominating Corporate Governance Committee Non-employee Director
Noncompetition Agreement Nonqualified Stock Option
Not Able Compete Successfully Other Companies Government Agencies Not Able Continue Development Lead Compounds Through Phase
Not Able Obtain Sufficient Additional Funding Meet Capital Not Able Protect Proprietary Rights Critical Success
Not Derive Revenues Diagnostic Tests Not Make Offer Relating Shares Constitute Issuer Free
Not Service Nor Employment Contract Not Successfully Develop Derive Revenues Products
Notes Condensed Consolidated Financial Statements Notice
Notice Annual Meeting Stockholders Held 2006 Notice Annual Meeting Stockholders Held 2007
Notice Annual Meeting Stockholders Held 2008 Notice Annual Meeting Stockholders Held 2009
Notice Termination Notices
Now Access Decode Genetics Inc Account Online Number 000-30469
Obesity Occupational Accidents Diseases
Ofac Only Indirect Evidence Biomarkers Studies Effectiveness Dg031 Data
Operating Activities Operations Involve Risk Injury Damage Hazardous Materials Accident
Opinion Davis Polk Wardwell Counsel Initial Purchasers Opinion Hamilton Brook Smith Reynolds Intellectual Property Counsel
Opinion Heslin Rothenberg Farley Mesiti Intellectual Property Counsel Opinion Marshall Gerstein Borum Llp Intellectual Property Counsel
Opinion Stevens Lee Opinion Stevens Lee Counsel
Option Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Optionee Options
Order Conduct Clinical Trials Market Drugs Develop Methods Order Decode
Organization Business Other
Other Commitments Other Compensation
Other Current Assets Other Events
Other Investors Other Matters
Other Non-operating Income Expense Net Other Non-operating Income Net
Other Officer Overview
Ownership Shares Pad
Pad Dg041 Pain
Pain Dg061 Paod
Participant Participant Employee Consultant Non-employee Director Award Been Granted
Participation Administrator Shall Grant Awards Only Persons Employees Parties
Party Compound Asthma Party Reimbursement Health Care Reform Policies Reduce Market
Party Reimbursement Healthcare Reform Policies Reduce Market Acceptance Patent Applications Covering Dg041 Dg051 Compounds Developing Pain
Patent Applications Covering Dg041 Dg051 Dg061 Not Issued Patent Applications Covering Dg041 Dg051 Not Issued Yet
Patent Applications Covering Dg041 Dg071 Not Issued Yet Patent Costs
Patent Protection Dg031 Provide Marketing Exclusivity Only Limited Patent Protection Obtain Products Not Prevent Marketing Similar
Patents Obtain Challenged Producers Generic Drugs Patents Proprietary Rights
Payments Benefits Chief Executive Officer Change Control Occurs Payments Benefits Designated Employees Termination Following Change Control
Payments Benefits Reporting Officers Change Control Occurs Then Payments Termination Change Control
Pde4 Inhibitors Vascular Disease Stroke Pde4 Vascular Disease Stroke
Performance Based Cash Compensation Performance Criteria
Performance Goal Performance Grant
Performance Grants Not Mandatory Nothing Herein Shall Construed Peripheral Artery Disease Pad Dg041
Permitted Issuer Information Person
Person Holding Option Relevant Time Accordance Provisions Plan Personnel
Persons Entitled Benefit Agreement Peter Goodfellow
Pharmacokinetic Profile Phase Clinical Trial Dg031 Require Recruitment Patients Based
Pioneering Human Genetics Target Causative Biology Leading Cause Pipeline Dg031 Prevention Heart Attack
Pipeline Dg041 Treatment Atherosclerosis Paod Placement Agency Agreement
Placement Agents Placement Agents Information
Plan Decode Genetics Inc 2006 Equity Incentive Plan Governs
Positive Clinical Results Dg041 Lead Product Development Highlights Positive Results Phase Iia Study Pave Way Iib
Powers Administrator Preferred Stock
Preliminary Prospectus Premises Agreement
Prevailing Market Rent Price Common Stock Volatile Market Value Investment Decrease
Price Delivery Pricewaterhousecoopers Llp
Principal Accountant Fees Services Principal Effects Reverse Stock Split
Principles Consolidation Procedure Effecting Reverse Stock Split Exchange Certificates
Product Development Product Portfolio Development Pipeline
Products Progress Clinical Preclinical Programs Senior Drug Development Appointments
Progress Developing Dna-based Diagnostics Type Diabetes Heart Attack Promptly Time Take Such Action Placement Agents Reasonably
Properties Property Equipment
Prospectus Prostate Cancer
Provided Provided However
Proxy Solicited Behalf Board Directors 2005 Annual Meeting Purported Termination Designated Employees Employment Not Effected Pursuant
Purpose Purpose Plan Types Awards
Pursuant Securities Exchange Act 1934 Quan
Quantitative Qualitative Disclosures Market Risk Qui Tam
Ratification Appointment Independent Registered Public Accounting Firm Reasons Reverse Stock Split
Recent Accounting Pronouncements Recent Clinical Studies Support Development Dg041 Effective Anti-platelet
Reclassifications Recommendation
Record Holder Reduction Benefits
Reference Value Reference Value Dollar Amount Fixed Such Date Grant
Registration Statement Regulation Disclosure
Regulatory Approvals Products Not Obtained Able Derive Revenues Regulatory Approvals Products Resulting Gene Discovery Programs Not
Release Release Parcel
Reliance Icelandic Population Limit Applicability Discoveries Certain Populations Relocation Designated Employees Principal Site Employment State United
Rely Single Laboratory Facility Process Diagnostic Test Decodeme Report Independent Registered Public Accounting Firm
Reporting Officer Representations Warranties Agreements Represents Warrants Agrees
Resale Registration Rights Agreement Research Analyst Independence
Research Development Research Development Cost Revenue Expenses
Research Development Expenses Research Development Programs
Research Development-proprietary Programs Research Funding Other Service Fees
Reservation Right Abandon Reverse Stock Split Responsibilities
Restatement Financial Statements Restricted Stock
Restricted Stock Agreement Results
Results Operations 2005 2004 2003 Results Operations 2006 2005 2004
Results Operations 2007 2006 2005 Results Operations 2008 2007 2006
Results Operations Financial Condition Results Operations Nine-month Periods 2007 2006
Results Operations Nine-month Periods 2008 2007 Results Operations Six-month Periods 2007 2006
Results Operations Six-month Periods 2008 2007 Results Operations Six-month Periods 2009 2008
Results Operations Three-month Periods 2008 2007 Results Operations Three-month Periods 2009 2008
Retirement Revenue
Revenue Recognition Rights Stockholder
Risk Common Stock Being De-listed Nasdaq Risk Factors
Risk Factors Forward-looking Statements Cautionary Affect Future Results Risks Related Business
Risks Related Collaborative Relationships Risks Related Development Dg031
Role Executive Officers Determining Compensation Rug Discovery Development Services
Rule 13d-3 Such Act Percent Common Stock Corporation Safety Tolerabilit
Sale Common Stock Sale Encode
Sale Leaseback Sale-leaseback Financing
Sar Sarbanes-oxley Act 2002
Schedule Schedule 14a
Schizophrenia Securities Act
Securities Act 1933 Amended Securities Exchange Act 1934
Securities Exchange Washington 20549 Form 10-q Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Selected Quarterly Data
Selling General Administrative Expense Senior Convertible Notes
Severance Change Control Arrangements Shall Delivered Sent Mail Facsimile Transmission Address Set
Share Adjustments Share Based Payments
Share-based Payment Shares Common Stock Outstanding Prior Issuance Been Duly
Shares Outstanding Quorum Shares Subject 2006 Plan
Short Term Borrowings Short-term Borrowings
Signature Signatures
Significant Collaborations Significant Customers
Skin Cancer Some Parts Product Development Services Create Risk Liability
Special Termination Provisions Options Statement Cash Flows
Stock Appreciation Rights Stock Appreciation Rights Sars
Stock Based Compensation Remuneration Expense Stock Option Grants
Stock Options Stock Options General
Stock Ownership Guidelines Stock Powers Time Grant Restricted Award Participant Shall
Stock-based Compensation Stock-based Compensation Remuneration
Stockholder Communication Stockholder Communications
Stockholder Proposals 2006 Annual Meeting Stockholders Stockholder Proposals 2007 Annual Meeting Stockholders
Stockholder Proposals 2008 Annual Meeting Stockholders Stockholder Proposals 2009 Annual Meeting Stockholders
Stockholder Proposals 2010 Annual Meeting Stockholders Stockholders Asked Complete Sign Date Enclosed Proxy Card
Stockholders Entitled Vote Strategic Review
Strategy Approach Genes Drugs Strategy Approach Genes Products
Sturlugata Sturlugata Is-101 Reykjavik Iceland
Sturlugata Is-101 Reykjavík Iceland Sturlugata Reykjavík
Sub-lease Right Refusal Lease Buy Subject Terms Provisions Conditions Plan Administrator Shall Exclusive
Submission Matters Vote Security Holders Submits Ind Novel Anti-atherosclerosis Compound Dg041
Subsequent Event Subsequent Events
Subsidiaries Decode Genetics Inc Subsidiaries Islensk Erfdagreining Ehf
Subsidiaries Medichem Life Sciences Inc Subsidiary
Substantial Portion Participants Genetics Research Studies Withdraw Informed Successors Assigns Heirs
Suspension Phase Trial Dg031 Delay Completion Possible Commercialization Table Contents
Tandem Sar Tandem Sar Granted Connection Concurrent Grant Option Shall
Target Discovery Targeting Leukotriene Pathway Prevention Heart Attack Dg051 Dg031
Term Employment Term Lease Delivery Property
Term Vesting Exercise Options Termination Dismissal Cause
Termination Employment Following Change Control Termination Plan Unless Previously Terminated Board Shall Terminate
Terms Conditions Purchase Shares Terrance Mcguire
Therapeutic Diagnostic Products Developed Result Programs Product Liability Therapeutics
Therapeutics Heart Attack Atherosclerosis Asthma-successfully Focusing Resources Advancing Tia
Time Sale Prospectus Titative Qualitative Disclosures Market Risk
Transfer Restricted Securities Transferability
Transferability Options Trols Procedures
Type Diabetes Type Diabetes Major Public Health Problem
Unable Form Maintain Collaborative Relationships Business Strategy Requires Unable Hire Retain Key Personnel Success Depends
Uncertainties United States Bankruptcy Court District Delaware
Up-front Exclusivity Technology Access Development Fees Uvs
Vacation Valuation Techniques
Vascular Disease Stroke Vesting Forfeiture
Vitro Vote
Votes Counted Wage Terms
Waiver Warrants
Whereas Withholding
Withholding Taxes Woodridge
Working 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki